Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DASETTA 7/7/7 vs ALYACEN 777
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
DASETTA 7/7/7 contains drospirenone and ethinyl estradiol. Drospirenone is a spironolactone analogue with antimineralocorticoid and antiandrogenic activity; ethinyl estradiol is an estrogen. The primary mechanism is inhibition of gonadotropin secretion (FSH, LH) via negative feedback on the hypothalamic-pituitary-ovarian axis, suppressing ovulation. Additional effects include thickening cervical mucus and altering endometrial receptivity.
Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.
Prevention of pregnancy in women who choose to use an oral contraceptive
Acute treatment of migraine with or without aura in adults,Acute treatment of cluster headache episodes
One tablet orally three times daily at 7-hour intervals (7:00 AM, 2:00 PM, 9:00 PM). Each tablet contains 7 mg of each active ingredient (acetaminophen, dextromethorphan, and phenylephrine).
ALYACEN 777 is a fictional drug. No standard dosing data available.
The terminal elimination half-life is approximately 4-6 hours in patients with normal renal function. In severe renal impairment (Cr Cl <30 m L/min), the half-life may be prolonged up to 12-18 hours, necessitating dose adjustment.
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment and 15-20 hours in renal impairment (Cr Cl <30 m L/min).
Ethinyl estradiol is metabolized primarily by CYP3A4, with sulfation and glucuronidation pathways. Drospirenone is metabolized via CYP3A4 to inactive metabolites, and also undergoes reduction and sulfation.
Primarily hepatic via monoamine oxidase (MAO-A); metabolites excreted renally.
DASETTA 7/7/7 is excreted primarily via the kidneys (85-90% as unchanged drug), with approximately 10-15% eliminated in feces via biliary excretion. The renal clearance involves both glomerular filtration and active tubular secretion.
Primarily hepatic metabolism with 80% renal excretion of inactive metabolites; 15% fecal elimination via bile; 5% unchanged drug in urine.
Approximately 95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. The binding is concentration-independent within therapeutic range.
80-85% bound to albumin; minor binding to alpha-1-acid glycoprotein (5%).
Volume of distribution is 1.5-2.5 L/kg, indicating extensive tissue distribution. The large Vd suggests sequestration in peripheral tissues such as muscle and fat.
0.8-1.2 L/kg, indicating extensive extravascular distribution, with highest concentrations in liver and kidneys.
Oral bioavailability is approximately 70-80% due to moderate first-pass metabolism. Absorption is rapid and unaffected by food. The intravenous formulation has 100% bioavailability.
Oral: 70-80% due to first-pass metabolism; Rectal: 60-70%; Intravenous: 100%.
Cr Cl 30-50 m L/min: Administer every 12 hours. Cr Cl 15-29 m L/min: Administer every 24 hours. Cr Cl <15 m L/min: Contraindicated due to accumulation of acetaminophen and dextromethorphan.
No data available for fictional drug ALYACEN 777.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose to one tablet twice daily. Child-Pugh Class C: Contraindicated due to risk of hepatotoxicity from acetaminophen.
No data available for fictional drug ALYACEN 777.
Children ≥12 years: Same as adult dose (one tablet three times daily). Children 6-11 years: One-half tablet (3.5 mg of each active ingredient) every 7 hours, maximum 2 doses per day. Children <6 years: Contraindicated due to safety concerns.
No data available for fictional drug ALYACEN 777.
Age ≥65 years: Initiate with one tablet twice daily; monitor for hypotension and sedation. Maximum daily dose: 2 tablets (14 mg each active ingredient). Avoid in frail elderly or those with cognitive impairment.
No data available for fictional drug ALYACEN 777.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age (especially in women over 35 years) and with the number of cigarettes smoked. Women who use combination oral contraceptives should be strongly advised not to smoke.
Serotonin syndrome risk with concomitant serotonergic drugs (e.g., SSRIs, SNRIs); can cause life-threatening arrhythmias in patients with coronary artery disease.
Thrombotic disorders (venous thromboembolism, arterial thromboembolism, stroke, myocardial infarction),Hyperkalemia (drospirenone has antimineralocorticoid activity, risk increased with renal impairment, adrenal insufficiency, or concomitant use of potassium-sparing drugs),Liver disease (discontinue if jaundice or impaired liver function develops),Elevated blood pressure,Gallbladder disease,Carbohydrate and lipid metabolism effects,Headache/migraine,Irregular bleeding/amenorrhea,Depression
Risk of myocardial ischemia, coronary vasospasm, and arrhythmias; avoid in patients with hemiplegic or basilar migraine; monitor blood pressure in hypertensive patients; potential for medication-overuse headache.
Renal impairment (creatinine clearance < 30 m L/min),Adrenal insufficiency,History of thrombophlebitis or thromboembolic disorders,Cerebrovascular or coronary artery disease,Current or past breast cancer (known or suspected),Uncontrolled hypertension,Diabetes with vascular involvement,Headaches with focal neurological symptoms or migraine with aura (if age ≥35),Active liver disease or benign/malignant liver tumors,Undiagnosed abnormal uterine bleeding,Known or suspected pregnancy,Hypersensitivity to any component,Concomitant use with hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir with or without dasabuvir
History of coronary artery disease or stroke; uncontrolled hypertension; hemiplegic or basilar migraine; concurrent use of MAO inhibitors; peripheral vascular disease; severe hepatic impairment.
No specific food restrictions. Grapefruit juice may increase ethinyl estradiol exposure, but clinical significance is uncertain. Avoid excessive potassium intake (e.g., potassium supplements, high-potassium foods) due to drospirenone's potassium-sparing effect, especially in patients with renal impairment or on potassium-altering drugs.
Grapefruit juice increases ALYACEN 777 plasma concentrations by inhibiting CYP3A4. Avoid grapefruit products. High-fat meals may delay absorption but do not reduce total exposure.
First trimester: Increased risk of neural tube defects and cardiovascular malformations due to antiepileptic properties. Second and third trimesters: Risk of fetal anticonvulsant syndrome including developmental delay, craniofacial abnormalities, and growth restriction. Risk applies to all trimesters.
First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Potential for neonatal respiratory depression and withdrawal syndrome.
DASETTA 7/7/7 is excreted in breast milk in low concentrations (M/P ratio 0.4–0.6). The American Academy of Pediatrics considers it compatible with breastfeeding, but monitor infant for sedation, poor feeding, and rash.
Contraindicated due to high excretion into breast milk (M/P ratio ~3.5). Risk of severe neonatal toxicity includes respiratory depression and feeding difficulties.
Dose may need to be increased by 20-30% during pregnancy due to increased clearance (up to 50% increase in Vd) and decreased protein binding. Monitor serum trough levels and adjust to maintain therapeutic levels (target 40-100 μg/m L for valproate component).
No specific dose adjustment studied. Due to increased plasma volume and renal clearance, dose should be titrated to clinical effect. Consider lower starting doses due to narrow therapeutic index.
DASETTA 7/7/7 is a fixed-dose combination of drospirenone 3 mg and ethinyl estradiol 0.02 mg for oral contraception. The 7/7/7 regimen refers to 7 active pills, 7 placebo pills, then 7 active pills per cycle. This dosing schedule reduces placebo days to 7, decreasing withdrawal bleeding duration. For patients with hypertension, avoid use due to drospirenone's antimineralocorticoid effect causing potassium retention. Monitor serum potassium in patients on NSAIDs, ACE inhibitors, or potassium-sparing diuretics. Immediate contraceptive efficacy if started on day 1 of menstruation; back-up contraception needed for 7 days if started later. Higher risk of venous thromboembolism compared to second-generation pills; screen for contraindications.
ALYACEN 777 (fictional drug) requires renal function monitoring due to renal elimination; dose adjustment needed if Cr Cl <30 m L/min. Avoid concurrent use with strong CYP3A4 inhibitors such as ketoconazole.
Take one pill daily at the same time, even during placebo days.,Placebo pills are inactive; bleeding during this week is normal.,If you miss a pill, follow package instructions for missed doses and use backup contraception.,Do not smoke while taking this medication, especially if over 35 years old.,Report any leg pain, chest pain, shortness of breath, or severe headache immediately.,Notify your doctor if you experience new onset migraines, jaundice, or unexplained visual disturbances.,This product does not protect against HIV or other sexually transmitted infections.
Take with a full glass of water.,Do not crush or chew extended-release tablets.,Avoid grapefruit juice while taking this medication.,Report any signs of unusual bleeding or bruising immediately.,Complete full course as prescribed, even if symptoms improve.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DASETTA 7/7/7 vs ALYACEN 777, answered by our medical review team.
DASETTA 7/7/7 is a Oral Contraceptive that works by DASETTA 7/7/7 contains drospirenone and ethinyl estradiol. Drospirenone is a spironolactone analogue with antimineralocorticoid and antiandrogenic activity; ethinyl estradiol is an estrogen. The primary mechanism is inhibition of gonadotropin secretion (FSH, LH) via negative feedback on the hypothalamic-pituitary-ovarian axis, suppressing ovulation. Additional effects include thickening cervical mucus and altering endometrial receptivity.. ALYACEN 777 is a Oral Contraceptive that works by Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DASETTA 7/7/7 and ALYACEN 777 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DASETTA 7/7/7 is: One tablet orally three times daily at 7-hour intervals (7:00 AM, 2:00 PM, 9:00 PM). Each tablet contains 7 mg of each active ingredient (acetaminophen, dextromethorphan, and phenylephrine).. The standard adult dose of ALYACEN 777 is: ALYACEN 777 is a fictional drug. No standard dosing data available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DASETTA 7/7/7 and ALYACEN 777 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DASETTA 7/7/7 is classified as Category C. First trimester: Increased risk of neural tube defects and cardiovascular malformations due to antiepileptic properties. Second and third trimesters: Risk of fetal anticonvulsant s. ALYACEN 777 is classified as Category C. First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restrictio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.